Docoh
Loading...

VRNA Verona Pharma

GRANT
Utility
Liquid inhalation formulation comprising RPL554
16 Mar 21
The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof.
Peter Lionel Spargo, Edward James French, Phillip A. Haywood
Filed: 21 Mar 18
GRANT
Utility
Treatment
14 Dec 20
The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof.
Katharine Abbott-Banner, John Hanrahan, David Thomas
Filed: 10 May 15
GRANT
Utility
Compound and process
13 Jul 20
Peter Lionel Spargo
Filed: 26 Jul 17
APP
Utility
Salt of a PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE Compound
15 Jan 20
The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
Peter Lionel Spargo, Edward James French, Julian Scott Northen, John Mykytiuk
Filed: 23 Sep 19
GRANT
Utility
Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist
11 Nov 19
The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.
Michael J. A. Walker, Mario Cazzola, Luigino Calzetta
Filed: 4 Jun 17
GRANT
Utility
Salt of a pyrimido[6,1-A]isoquinolin-4-one compound
4 Nov 19
The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.
Peter Lionel Spargo, Edward James French, Julian Scott Northen, John Mykytiuk
Filed: 9 Feb 16
APP
Utility
New Compound and Process
30 Oct 19
Peter Lionel Spargo
Filed: 26 Jul 17
  • 1
Patents are sorted by USPTO publication date, most recent first